Cook Meredith sold 500 ANI Pharmaceuticals shares at $70.79 each on 2026-09-14, leaving 73,924 shares after the transaction. The sale represented about 0.7% of Meredith’s prior holding, giving investors a precise measure of the transaction’s size relative to the executive’s position.
Key Highlights
- Cook Meredith held 73,924 ANI Pharmaceuticals shares after the transaction.
- The transaction carried code S, denoting an open-market sale.
- The disposal represented about 0.7% of Cook Meredith’s prior holding.
ANI PHARMACEUTICALS INC (NASDAQ: ANIP) executive Cook Meredith sold 500 shares in the company. The transaction took place on 14 September 2026 at $70.79 per share.
Executive Sale Details
Cook Meredith is identified as ANI Pharmaceuticals’ SR. VP, GENERAL COUNSEL & SEC. Meredith held 73,924 shares after the transaction. The sale represented about 0.7% of Meredith’s prior share holding. The disclosed percentage measures the sale against Meredith’s previous holding.
FAQs
Q: How many ANI Pharmaceuticals shares did Cook Meredith sell?
A: Cook Meredith sold 500 ANI Pharmaceuticals shares at $70.79 per share. The transaction occurred on 14 September 2026 and was classified with code S.
Q: What was Cook Meredith’s ANI Pharmaceuticals holding after the sale?
A: Cook Meredith owned 73,924 ANI Pharmaceuticals shares after the transaction. Meredith is identified as the company’s SR. VP, GENERAL COUNSEL & SEC.
Q: What percentage of Cook Meredith’s prior holding did the sale represent?
A: The ANI Pharmaceuticals share sale represented about 0.7% of Cook Meredith’s prior holding. The disclosed percentage compares the transaction with Meredith’s earlier share position.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.